BERLIN, Germany and SEATTLE, March 22, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF) (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, will hold its annual press conference and analyst meeting on March 30, 2007 and present results for the fiscal year 2006. Geert Walther Nygaard, CEO and Oliver Schacht, CFO will give an overview of the operational developments as well as provide guidance for 2007. A conference call with Epigenomics' management will be held later on the same day.
Press Conference and Analyst Meeting
The press conference and analyst meeting will be conducted in German and will be held on Friday, March 30 2007 at 10 am to 11 am CET at the premises of the DZ Bank in Frankfurt:
DZ BANK AG Deutsche Zentral-Genossenschaftsbank Platz der Republik 60265 Frankfurt am Main Entrance Westend 1 Room: 38.08
Epigenomics asks interested parties to confirm their participation for the press conference and analyst meeting by Wednesday, March 28, 2007 by fax +49 (0)30 24345-555 or email ir@epigenomics.com.
Conference Call
A conference call will be held on Friday, March 30 2007 at 3pm to 4 pm CET (9am to 10 am EST), hosted by Epigenomics' management to discuss 2006 financial results and outlook for 2007. The conference call will be conducted in English.
Dial-in number (within Germany.): +49 6958 999 0804 Dial-in number (outside Germany): +1 480 293 1744
Please dial-in at least 10 minutes prior to commencement of the conference call.
To follow the presentation, Epigenomics kindly ask all participants of the call to download the slide set from the company website prior to the call where it will be made available as a PDF file at 10 am CET (4 am EST) on the same day.
Internet link: http://www.epigenomics.com/en/down_loads/corporate_material/
The conference call will be recorded and also made available on the company website web as a MP3 file after the call.
Internet link: http://www.epigenomics.com/en/down_loads/corporate_material/
About Epigenomics AG
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation markers, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics' defined business strategy covers two complementary core business areas:
In cooperation with industry partners, the company develops diagnostic screening tests for the early detection of cancer, mass-market products with huge potentials. Based on easily obtainable body fluid samples (e.g. blood and urine), these tests are aimed at finding cancer at an early stage before symptoms occur. Epigenomics' product pipeline contains an extensively validated biomarker panel for the early detection of colorectal cancer in blood plasma, and further proprietary DNA methylation biomarkers at various stages of development for prostate, lung and breast cancer detection in body fluids. Epigenomics has full flexibility to offer these programs as attractive partnering opportunities for global development, marketing and sales in the fast growing cancer molecular diagnostics market.
As a second core business area, Epigenomics develops tissue-based prognostic tests for prostate and breast cancer patients. With a strong focus on prostate cancer applications, these tests are developed in strategic partnerships with Qiagen (pre-analytics) and Affymetrix (diagnostic device platform). In this area Epigenomics also retains the flexibility to decide on potential partnerships for marketing and sales.
Pharma, diagnostics and biotech partners can access Epigenomics' portfolio of proprietary DNA methylation technologies protected by more than 200 patent families through Biomarker Services, IVD Development Collaborations, and Licensing. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, USA. For more information, please visit Epigenomics' website at www.epigenomics.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.